---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-003776"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:17:29.035287+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA reports Q4 net loss $12.3M, cash $113.4M; HB-200 data expected 2Q2023

## Summary
- Cash $113.4M at Dec 31, 2022, plus $15M milestones from Roche & Gilead in early 2023; no SVB exposure.
- Q4 revenue $7.8M, full-year $14.2M (down from $18.4M); net loss $64.9M for 2022 vs $75.7M in 2021.
- HB-200 Phase 2 data (with pembrolizumab) due 2Q2023; HB-300 trial open; HB-700 IND planned 1H2024.
- Roche collaboration: $10M milestone Feb 2023; potential milestones up to $930M plus royalties.
- Gilead HBV milestone $5M Jan 2023; HIV program IND expected 2023; HB-101 program discontinued.

## SEC filing metadata
- accession: 0001558370-23-003776
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/0001558370-23-003776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/hook-20230315x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-003776
- JSON: https://secwatch.observer/filing/0001558370-23-003776.json
- Plain text: https://secwatch.observer/filing/0001558370-23-003776.txt

## Key facts
- Earnings Releases
  HOOKIPA Pharma Inc. reported financial results for Fourth Quarter and Full Year 2022.
  - Period: Fourth Quarter and Full Year 2022
  - Result: reported results
  source text: On March 15, 2023, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000155837023003776/0001558370-23-003776-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.